| Budget Amount *help |
¥17,810,000 (Direct Cost: ¥13,700,000、Indirect Cost: ¥4,110,000)
Fiscal Year 2022: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2021: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2020: ¥7,930,000 (Direct Cost: ¥6,100,000、Indirect Cost: ¥1,830,000)
|
|---|
| Outline of Final Research Achievements |
This project aimed to establish a versatile reverse genetic technique for "translation products," which are the end products of the central dogma. The goal was to develop artificial enzymes that are effective in vivo, can be designed into any endogenous protein, and induce degradation. Our investigations using oocytes, preimplantation embryos, and individual mice suggested that proteolytic tools utilizing the E3 ubiquitin ligase complex-related genes can be used for novel reverse genetic approaches for endogenous proteins.
|
